MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
Hosted on MSN50m
Merck Just Paid Investors: How Much Did They Receive?Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback